Abstract
Microsatellite stable (MSS) metastatic colorectal cancer (mCRC) is one of the tumor type in which PD-1 inhibitor as monotherapy has proven less effective. Studies have shown that anti-VEGF therapies may enhance anti-PD-1 efficacy and microbiome-based therapies can overcome resistance to anti-PD-1. This study was to explore the efficacy and safety of fecal microbiota transplantation (FMT) combined with anti-VEGF and anti-PD-1 therapy in advanced mCRC with MSS.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
